Industry

BOTHELL, Wash.–(BUSINESS WIRE)–The MolinaCares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Washington (“Molina”), recently committed $400,000 to the University of Washington School of Nursing to help expand the behavioral health workforce in the state through the development and implementation of a blended family and psychiatric primary care curriculum for nurse practitioners. “MolinaCares is dedicated … [Read more…]

Current Patents and Planned Future Patent Applications Covers the Company’s Lead Product Candidate, PRP, and Backup Clinical Compounds MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that CEO and Co-Founder, Mr. James Nathanielsz, BAS, MEI, … [Read more…]

— Results Continue to Support that STAR-0215 is a Potent, Selective, and Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein — — STAR-0215 Demonstrates Rapid and Sustained Inhibition of Plasma Kallikrein After Subcutaneous Administration in Monkeys — BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for … [Read more…]

LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will be participating in a fireside chat at the William Blair … [Read more…]

Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today CAMBRIDGE, … [Read more…]

Board of Directors continues its review of strategic alternatives to determine the Company’s optimal path forward CARLSBAD, Calif.–(BUSINESS WIRE)–$RMED #Atherectomy–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”), a medical device company focusing on developing its excimer laser system to treat vascular diseases, announces receipt of U.S. Food and Drug Administration 510(k) … [Read more…]

– Sebetralstat data examines efficacy by attack location and population PK comparisons – – Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system – CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease … [Read more…]

SHENZHEN, China–(BUSINESS WIRE)–SMOORE, the world’s largest vape manufacture, today announced it has launched the world’s first real-time monitoring research project on nicotine addiction. In partnership with the Shenzhen Institute of Advanced Technology (SIAT), SMOORE’s new research project aims to explore how best to minimize the nicotine strength in vaping products and ultimately to bring it … [Read more…]

The Finance Platform is Partnering with CCRM Fertility to Offer the First-Of-Its-Kind Plan to Patients SAN FRANCISCO–(BUSINESS WIRE)–Today, Future Family, the only fertility finance platform to pair a modern fintech experience with client care and wellness support, announced that it will add a 0% interest rate fertility financing program to its offerings. This first-of-its-kind plan … [Read more…]

Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the “Company” or … [Read more…]